{"title":"Toad Poisoning: Clinical Characteristics and Outcomes.","authors":"Satariya Trakulsrichai, Kritsada Chumvanichaya, Charuwan Sriapha, Achara Tongpoo, Winai Wananukul","doi":"10.2147/TCRM.S272863","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study was performed to describe the clinical characteristics and outcomes of patients with toad poisoning in Thailand.</p><p><strong>Methods: </strong>We carried out a retrospective study of patients with toad poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year period (2012-2016).</p><p><strong>Results: </strong>We studied 36 patients poisoned by toad toxin. The median age was 31 years. Most patients were male (66.7%) and had ingested toad meat (50%). The most common presentation was gastrointestinal (GI) symptoms with a median onset of 2 h after ingestion. Twelve patients presented with bradycardia; seven presented with shock and one with cardiac arrest. In the initial EKGs of all patients, the most common abnormality was sinus bradycardia.Two patients developed cardiac arrest early during management in the emergency room (within 15 minutes after ER arrival or within 4.5 h after ingestion). During admission, one patient developed sinus bradycardia, and two developed bradyarrhythmia; however, all three were stable. No tachyarrhythmias such as ventricular tachycardia were detected in any patient. Some patients (11.1%) presented with hyperkalemia. Serum digoxin was detected in five of seven patients tested, ranging from 0.43 to >8 ng/mL. Most patients (75%) were admitted to the hospital; the median duration of hospitalization was 2 d (range 0.5-5 d). The overall mortality rate was 8.3%, and all three patients that died ate toad meat and/or eggs and developed cardiac arrest. All patients received supportive with/without symptomatic care including GI decontamination, inotropic drugs, cardiac pacing, and management of hyperkalemia. One patient received intravenous calcium for hyperkalemia but did not develop dysrhythmia after calcium administration. One patient received digoxin-specific antibody fragments (DsFab), after which he clinically improved and was discharged.</p><p><strong>Conclusion: </strong>Toad poisoning commonly caused GI symptoms and bradycardia. However, in severe cases, death occurred. Tachyarrhythmia was not observed. Supportive, symptomatic care might be the main therapies for this poisoning, especially if DsFab is not available.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"16 ","pages":"1235-1241"},"PeriodicalIF":2.3000,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/bd/tcrm-16-1235.PMC7752649.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S272863","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 3
Abstract
Objective: This study was performed to describe the clinical characteristics and outcomes of patients with toad poisoning in Thailand.
Methods: We carried out a retrospective study of patients with toad poisoning from the Ramathibodi Poison Center Toxic Exposure Surveillance System during a 5-year period (2012-2016).
Results: We studied 36 patients poisoned by toad toxin. The median age was 31 years. Most patients were male (66.7%) and had ingested toad meat (50%). The most common presentation was gastrointestinal (GI) symptoms with a median onset of 2 h after ingestion. Twelve patients presented with bradycardia; seven presented with shock and one with cardiac arrest. In the initial EKGs of all patients, the most common abnormality was sinus bradycardia.Two patients developed cardiac arrest early during management in the emergency room (within 15 minutes after ER arrival or within 4.5 h after ingestion). During admission, one patient developed sinus bradycardia, and two developed bradyarrhythmia; however, all three were stable. No tachyarrhythmias such as ventricular tachycardia were detected in any patient. Some patients (11.1%) presented with hyperkalemia. Serum digoxin was detected in five of seven patients tested, ranging from 0.43 to >8 ng/mL. Most patients (75%) were admitted to the hospital; the median duration of hospitalization was 2 d (range 0.5-5 d). The overall mortality rate was 8.3%, and all three patients that died ate toad meat and/or eggs and developed cardiac arrest. All patients received supportive with/without symptomatic care including GI decontamination, inotropic drugs, cardiac pacing, and management of hyperkalemia. One patient received intravenous calcium for hyperkalemia but did not develop dysrhythmia after calcium administration. One patient received digoxin-specific antibody fragments (DsFab), after which he clinically improved and was discharged.
Conclusion: Toad poisoning commonly caused GI symptoms and bradycardia. However, in severe cases, death occurred. Tachyarrhythmia was not observed. Supportive, symptomatic care might be the main therapies for this poisoning, especially if DsFab is not available.
目的:本研究描述泰国蟾蜍中毒患者的临床特征和预后。方法:回顾性研究Ramathibodi中毒中心毒性暴露监测系统5年间(2012-2016年)蟾蜍中毒患者。结果:对36例蟾蜍毒素中毒患者进行了研究。中位年龄为31岁。大多数患者为男性(66.7%),并有蟾蜍肉摄入(50%)。最常见的表现是胃肠道(GI)症状,中位发病时间为摄入后2小时。12例患者出现心动过缓;7人休克,1人心脏骤停。在所有患者的初始心电图中,最常见的异常是窦性心动过缓。2例患者在急诊室处理过程中早期出现心脏骤停(在急诊室到达后15分钟内或进食后4.5小时内)。入院时1例出现窦性心动过缓,2例出现慢性心律失常;然而,这三个都是稳定的。所有患者均未发现室性心动过速等快速心律失常。部分患者(11.1%)表现为高钾血症。7例患者血清中有5例检测到地高辛,范围从0.43到>8 ng/mL。大多数患者(75%)住院;中位住院时间为2 d (0.5-5 d),总死亡率为8.3%,死亡的3例患者均食用蟾蜍肉和/或鸡蛋并发生心脏骤停。所有患者均接受支持性治疗,包括胃肠道净化、肌力药物、心脏起搏和高钾血症管理。1例患者因高钾血症接受静脉补钙治疗,但补钙后未出现心律失常。1例患者接受地高辛特异性抗体片段(DsFab)治疗,临床好转后出院。结论:蟾蜍中毒常引起胃肠道症状和心动过缓。然而,在严重的情况下,会发生死亡。未观察到心动过速。支持性的对症治疗可能是这种中毒的主要治疗方法,特别是在没有DsFab的情况下。
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.